Skip to main content
. 2014 Jul 8;5(9):784–792. doi: 10.1021/cn500133b

Figure 4.

Figure 4

In vivo characterization of three VS hit compounds. (A) Naïve C57Bl/6J mice treated with TN-01 (0.5 mg/kg, n = 6 or 5 mg/kg, n = 5) showed significant decreases in immobility in the tail suspension test compared to saline-treated mice (n = 6). (p = 0.016; Dunnett’s test *p < 0.05 compared to saline.) (B) Naïve mice treated with TN-06 (1 mg/kg, n = 6; 10 mg/kg, n = 7; 20 mg/kg, n = 6) showed a significant decrease in immobility at the highest dose compared to saline (n = 6). (p = 0.018; Dunnett’s test *p < 0.05 compared to saline.) (C) Naïve mice treated with TN-13 (1 mg/kg, n = 6; 10 mg/kg, n = 6; 20 mg/kg, n = 6) showed a significant decrease in immobility with the two highest doses compared to saline (n = 6). (p = 0.0064; Dunnett’s test *p < 0.05, **p < 0.01 compared to saline.) The distance traveled in an open field compared to saline-treated mice (n = 5) is shown for mice treated with (D) TN-01 (5 mg/kg, n = 6), (E) TN-06 (20 mg/kg, n = 5), or (F) TN-13 (1 mg/kg, n = 3; 10 mg/kg, n = 3).